Background and objective: Reduced lung function and high lipoprotein (a) (Lp(a)) levels are both recognized risk factors for cardiovascular disease. Few studies have investigated the association between serum Lp(a) and lung function in the general population. We evaluated the association between reduced lung function and high Lp(a) levels in healthy individuals without known medical disease diagnoses. Methods: We performed a cross-sectional study on 64 082 Korean health screening examinees (33 049 males, 38 AE 7 years) who underwent a health examination in 2015.
INTRODUCTION
Lipoprotein (a) (Lp(a)) is a low-density lipoprotein (LDL)-like particle that consists of an apoB100 molecule linked to the glycoprotein apolipoprotein (a). Serum Lp(a) levels vary widely among individuals and ethnicities in a distribution that is skewed towards lower levels, are largely determined by genetic background and remain relatively stable over an individual's lifetime. 1 High Lp(a) levels are associated with increased cardiovascular disease (CVD), cardiovascular mortality [1] [2] [3] [4] and rheumatoid factor (RF) positivity, 5 suggestive of an association with systemic inflammation and autoimmune activation, respectively. Reduced lung function is also linked to increased CVD risk and mortality 6 as well as RF positivity. 7 Systemic inflammation and autoantibodies may mediate the development of CVD and RF positivity, respectively, and through their actions may cause airspace inflammation leading to reduced lung function. 8, 9 Together, these results raise the possibility that high Lp(a) levels may be an indicator of increased susceptibility to reduction of lung function.
Three studies to date have attempted to evaluate the relationship between Lp(a) levels and lung function. Two studies compared patients suffering from chronic obstructive pulmonary disease (COPD) with healthy controls, 10, 11 and were relatively small in size and Figure 1 Selection of subjects. COPD, chronic obstructive pulmonary disease; HBsAg, hepatitis B virus surface antigen; HCV, hepatitis C virus. scope. Thus, only one study to date has evaluated the general population, although it was restricted to an elderly population (60-84 years). 12 Whereas a positive relationship between lung function and serum Lp(a) levels was noted in the population-based cohort study, 12 the results of the two case-control studies remain controversial. 10, 11 As a result, the relationship between Lp(a) and lung function is poorly understood at the population level, especially in Asians. Therefore, we aimed to investigate the association between serum Lp(a) levels and lung function in a large study population consisting of Korean health screening subjects.
METHODS

Study design and population
A total of 189 154 study subjects (age range: 18-82 years) participated in the health check-up programme held at Kangbuk Samsung Hospital Health Screening Centers, Republic of Korea, between January and December 2015. All subjects completed a physical activity questionnaire and underwent a comprehensive health examination.
A cohort of individuals with a recorded serum Lp(a) level and spirometry data (n = 127 499) was extracted from the initial study set. Among the potential study subjects, we excluded 63 417 participants with either a self-reported history and/or those patients currently receiving medication for any of the following conditions: diabetes or CVD including coronary artery disease, hypertension, dyslipidaemia, stroke and any other heart diseases (n = 22 834); chronic lung disease or abnormal chest radiograph findings (n = 18 477); thyroid disease (n = 8812); chronic liver disease including positive serological markers for hepatitis B or C virus (n = 6324); history of malignancy (n = 3707); chronic kidney disease (n = 2840); and current steroid use (n = 53). Detailed co-morbidity data were not specified, because the medical history questionnaire only required yes/no responses. We also excluded subjects with missing medical history data (n = 370). Finally, 64 082 subjects were available for the final analysis (Fig. 1) .
The study was approved by the Institutional Review Board of the Kangbuk Samsung Hospital, which waived the requirement for informed consent as we accessed and used only a de-identified database generated from routine health-screening exams.
Data collection, anthropometric measurements and laboratory tests
Information on demographic characteristics, smoking status, drinking habits, exercise frequency, medical history, current regular medication use and any clinical symptoms were collected by standardized, selfadministered questionnaires. Smoking status was classified as non-smoker, ex-smokers (not currently smoking but with a history of regular smoking) and current Continuous variables are expressed as the mean AE SD or median with interquartile range (IQR). Categorical variables are described as numbers and percentages. We recorded subject numbers with available clinical parameters. Unless otherwise indicated, the available subject number was 64 082.
† P < 0.001 compared with high Lp(a). ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, C-reactive protein; FEV 1 , forced expiratory volume in 1 s; FVC, forced vital capacity; LDL, low-density lipoprotein; Lp(a), lipoprotein (a).
smokers (at least one cigarette per day). Alcohol history was considered positive if the subject had used alcohol in the past, even if they had stopped drinking. The weekly frequency of moderate activity or exercise per week (moderate activity was defined as more than 30 min of activity per day that induced slight breathlessness) was also assessed, and regular exercise was defined as ≥3 times/week.
Physical characteristics and serum biochemical parameters were measured. Height and weight were estimated by trained nurses using automated instruments with individuals wearing a lightweight hospital gown and no shoes. Height was measured to the nearest 1 mm using a stadiometer with the participant standing barefoot. Body weight was measured to the nearest 0.1 kg on a bioimpedance analyser (InBody 3.0 and InBody 720, Biospace Co., Seoul, Korea) validated for reproducibility and accuracy of body composition measurements. 13 Body mass index (BMI) was calculated as weight in kilograms divided by height in metres squared (kg/m 2 ). Obesity was defined as a BMI ≥25 kg/m 2 , which is the proposed cut-off for Asian populations.
14 Blood pressures (BP) were measured by trained nurses with a standard sphygmomanometer after at least 5 min of seated rest. Measurements were performed twice at 5-min intervals and averaged for analysis. Mean BP was calculated as diastolic BP + 0.33
Blood samples were taken from after at least a 10-h fast. Methods for measuring serum levels of glucose, lipid profiles, liver enzymes, C-reactive protein (CRP) and HbA1c levels were performed as described previously. 15, 16 Serum Lp(a) concentrations were measured using an automatic chemistry analyser (Cobas 8000 c702; Roche Diagnostics, Tokyo, Japan) with Tinaquant lipoprotein(a) Gen.2 reagent (Roche Diagnostics GmbhepatH, Mannheim, Germany), which is a particle enhanced immunoturbidimetric assay that is proportional to the amount of Lp(a) in the specimen. Because Lp(a) > 30 mg/dL is the threshold value linked to pathological effects, we defined subjects with an Lp(a) of >30 mg/dL as having high Lp(a). 17 The Laboratory Medicine Department at Kangbuk Samsung Hospital is accredited and participates annually in inspections and surveys conducted by the Korean Association of Quality Assurance for Clinical Laboratories. 
Statistical analysis
Continuous variables are presented as the mean AE SD or median and interquartile range (IQR), while categorical variables are presented as a number and percentage. The normality of the distribution for all continuous variables was assessed by KolmogorovSmirnov test. All covariates were treated as categorical variables to analyse the significance of differences between subjects with a low Lp(a) and high Lp(a); high or low and with or without. Chi-square test or Fisher's exact test was used to assess the significance of differences between dichotomous variables.
Multivariate analysis with binary logistic regression was used to assess the association between FVC (L) or FEV 1 (L) quartiles and high Lp(a): model 1 was adjusted for age, gender and BMI; model 2 was adjusted as in model 1 plus smoking and alcohol; model 3 was adjusted as in model 2 plus variables with a P value <0.05 in univariate analysis. As FVC (L) and FEV 1 (L) were strongly correlated (r = 0.967, P < 0.001), these parameters were assessed separately to avoid confounding effects. The strength of associations was estimated using odds ratios (OR) and 95% CI. All tests were two-sided, and a P-value of <0.05 was considered statistically significant. Data were analysed using IBM SPSS Statistics 19.0 (IBM, Armonk, NY, USA).
RESULTS
The characteristics of the 64 082 eligible subjects (51.6% male, 38 AE 7 years) are summarized in Tables 1  and 2 . The median Lp(a) level was 12 (6-25) mg/dL, and the prevalence of a high Lp(a) was 19.5%. A total of 67% of the study population were non-smokers, and the proportion of non-smokers was higher in the high Lp(a) group compared with the low group (69.3% vs 66.3%, P < 0.001). Conversely, there were more nondrinkers in the low Lp(a) group than in the high Lp(a) group (24.1% vs 21.5%, P < 0.001). Subjects with a high Lp(a) had significantly lower values of measured FVC (L) and FEV 1 (L) than those with a low Lp(a). But, there was statistically insignificant in the FEV 1 /FVC ratio between groups (P = 0.112).
In univariate analysis, high Lp(a) was inversely associated with obesity, hyperglycaemia and hypertriglyceridaemia, and positively associated with cholesterol, LDL-C and CRP levels. The proportion of subjects with an elevated creatinine level did not vary between the two groups (P = 0.398) ( Table 3) . Multiple regression analysis was performed to assess whether FEV 1 (L) and FVC (L) were independently associated with the prevalence of a high Lp(a) ( Table 4 , Fig. 2 ). According to the fully adjusted logistic regression analysis, the risk of having a high Lp(a) was lower for subjects with a higher FEV 1 (L) and FVC (L) when subjects in the lowest quartile of lung function were defined as having the outcome of interest. Specifically, the adjusted OR for a high Lp(a) comparing the second, third and fourth quartiles to the lowest quartile of FVC (L) were 0.928 (95% CI: 0.876-0.982), 0.860 (0.808-0.916) and 0.895 (0.839-0.954), respectively (P for trend < 0.001). Similar results were observed across the predicted FEV 1 (L) quartiles (P for trend < 0.001).
DISCUSSION
The current study demonstrated that high Lp(a) was significantly associated with decreased FVC and FEV 1 . To our knowledge, this study is the first to describe this association between high Lp(a) and lung function in a middle-aged Korean population without overt clinical disease, supporting previous findings that CVD risk is increased in subjects with reduced lung function. 19, 20 Serum Lp(a) concentrations vary significantly in different ethnic populations. 1, 21 Overall prevalence of high Lp(a) defined as >30 mg/dL was 19.5% in this study. Although the prevalence of high Lp(a) has rarely been investigated in Korean health screening examinees without known medical disease, this proportion is generally comparable to those (about 20%) reported in apparently healthy Caucasian (Belgians and Hungarians), whereas this proportion was lower than those in healthy Africans (about 40-50%) 21 and those of previous studies including patients with diabetes, hypertension and coronary heart diseases (25-32.5%). 22, 23 Interestingly, our findings are contradictory to the results from the German elderly cohort study, 12 although it should be noted that the median age of enrolled subjects in that study was much higher than that of our study (median age: 68 years vs 38 years, respectively).
Thus, it is possible that the German cohort study may have included more subjects with subclinical hepatic dysfunction than our study. This is an important distinction, because Lp(a) is synthesized by liver. 24 Additionally, some subjects in the German cohort study had a history of diabetes (13%) and dyslipidaemia (16%), both of which are inversely associated with lung function 25, 26 and serum Lp(a) levels. 4 We excluded subjects with overt diabetes, dyslipidaemia and other diseases known to affect lung function and Lp(a) levels. 1, 4, 10 Thus, compared with the German study, our results may be more relevant to a general healthy population without existing lung function abnormalities and structural abnormalities. However, our results should be interpreted with caution, because of this modest effect of Lp(a) on lung function. In the actual population, a variety of factors such as smoking, air pollution and preexisting disease contributed more to decreased lung function than Lp(a), and vice versa. 1 Furthermore, we found no association between FEV 1 /FVC and high Lp(a). A possible explanation for this is that functional debility of the large airways might be undetected on the screening spirometry for healthy subjects. 27 Thus, although our study demonstrated a significant inverse association between high Lp(a) and lung function in a large study population, further prospective longitudinal studies are needed to determine whether Lp(a) is an independent risk factor for deterioration of lung function.
The underlying mechanisms behind the association of reduced lung function with high Lp(a) observed in our study remain unclear. A plausible explanation is that systemic inflammation mediates the link between reduced lung function and high Lp(a). Inhalation of noxious particulates could cause airspace inflammation leading to release of pro-inflammatory cytokines (such as IL-6 which is the chief stimulator of CRP production) from alveolar macrophages, which may result in damage to the airways and lead to a decline in lung function. 28 In addition, released inflammatory cytokines may enter the circulation and stimulate systemic inflammation, 28 which is an important mechanism for CVD. 29 Indeed, levels of CRP, a marker of systemic inflammation, correlate with those of Lp(a) 4 which itself plays a major role in the development of CVD. 30 Therefore, reduced lung function may be closely associated with high levels of Lp(a) that precede the development of CVD.
Previous reports have suggested that low Lp(a) is associated with reduced lung function, as in the German study described above, and also a COPD cohort study. 10, 12 Reduced lung function including COPD 19, 20, 31 and high Lp(a) [1] [2] [3] [4] are well-known powerful risk factors for CVD and CVD-associated morbidity and mortality, owing to enhanced systemic inflammation. [1] [2] [3] [4] 8, 32 However, the mechanisms for these interesting results are not fully understood. A previous study demonstrated that the imparted cardiometabolic risk is higher for the two extreme tertiles of Lp(a) compared with the mid-tertiles. 33 Lp(a) binds pro-inflammatory oxidized phospholipids. 34 Oxidation-specific epitopes on circulating Lp(a) are markers for increase in pro-inflammation and autoimmune response, which are major determinants for cardiometabolic events. 5 Thus, low Lp(a) levels may represent trapping of Lp(a) by enhanced autoimmune processes, and in this way elevated cardiometabolic risk may be conferred by reduced circulating Lp(a) levels. 5 As a result, enhanced inflammation and autoimmune activation can result in either excess or decreased levels of circulating Lp(a). For this reason, careful consideration is required when assessing the relationship between lung function and Lp(a), especially in subjects of advanced age or with preexisting or subclinical cardiometabolic disease, such as the German study and COPD cohort study. 10, 12 There are several limitations to our study that should be discussed. First, due to the cross-sectional design of this study, we were unable to establish a causal relationship between Lp(a) and lung function. Thus, further longitudinal follow-up studies will be required to establish the directionality of this relationship. Second, there is the possibility of selection bias in this study, as the participants were mostly middle-aged residents of an urban community in Korea enrolled in check-up programmes at a single university hospital. Therefore, caution should be used when generalizing our data to other populations or ethnic groups, especially considering the wide range of serum Lp(a) levels among different individuals and ethnicities 1 Finally, the true incidence of lung disease and cardiometabolic disease could has been underestimated in our study due to the questionnaire-based collection of medical histories. This may be significant, as the relationship between subclinical cardiometabolic disease can contribute to a decline in lung function, especially among individuals with high Lp(a) levels.
In conclusion, we found that high Lp(a) levels (based on the suggested high risk value for CVD) were inversely associated with lung function in a healthy middle-aged Korean population. However, longitudinal follow-up studies and prospective interventional studies are needed to validate our findings.
